Search Medical Condition
Please enter condition
Please choose location

Oral Cavity Cancer Clinical Trials

A listing of Oral Cavity Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (56) clinical trials

Pembrolizumab in Combination With CRT for LA-SCCHN

Each subject will participate in the trial from the time the subject signs the Informed Consent Form (ICF) through the final protocol-specified contact. After a screening phase of 28 days, eligible subjects will receive treatment on Day -7 with a loading dose of the study drug. This will continue during ...

Phase

Validation of DNA Methylation Biomarkers for Oral Cancer Detection

In this study, investigators plan to recruit 40~50 patients who had, or currently has oral cancer. The study procedures are as below: - After the Informed Consent Form is signed, swab from the lesion site and normal site to obtain oral epithelial cells. - Collect tissue from the tumor site ...

Phase N/A

Patient Evaluation for Head and Neck Surgery Branch Studies

This protocol will provide a means for screening potential candidates for head and neck surgery branch protocols. No investigational treatments will be administered in this protocol. The PI may, however, approve a patient who has been determined to be ineligible for HNSB protocols to undergo standard treatment because they present ...

Phase N/A

NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx

Patients will receive a single administration of NBTXR3 on day 1, either as an intra-arterial or intratumor injection, followed by Intensity Modulated Radiation Therapy starting 24 hours later (day 2), and up to completion of 7 weeks, i.e. 70 Grays, 2Grays/fraction. Patients whose tumor has completely shrunk will be followed ...

Phase

Fluorescence & Reflectance Imaging to Detect Oral Neoplasia

The Imaging Methods: All tissue and cells are made of tiny particles. Some of these particles give off small amounts of light. This light is called fluorescence. Researchers have learned that cancerous cells and normal cells give off different amounts and different types of fluorescence and also reflect light differently. ...

Phase N/A

Impact of Compliance With Fluoride Use on Caries Incidence After Cancer Therapy

This research proposal is unique in that it compares two different methods of applying neutral sodium fluoride to prevent dental caries and improve compliance in this at-risk population. Given that compliance with use of fluoride trays has historically been poor, there is controversy as to which application method is best. ...

Phase N/A

Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions

PRIMARY OBJECTIVE: I. Determine the effect of ZD6474 (vandetanib) compared to placebo on microvessel density (MVD) from baseline to 3 months in patients at risk for oral squamous cell carcinoma (OSCC) with preneoplastic lesions. SECONDARY OBJECTIVES: I. Change in MVD over 6 months. II. Change in putative targets of ZD6474: ...

Phase

Screening for Cancers in the Oral CAvity

Methodology Education and alerting physicians to the early detection of cancers of oral cavity and coordination of networks involved for 1 year. Incentive period for the screening by the tobacconist who distributes with every package of cigarettes bought a flyer of invitation to the screening. Carrying out screening examinations by ...

Phase N/A

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer

PRIMARY OBJECTIVES: I. Determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) when given in combination with FHX (5 fluorouracil [fluorouracil], hydroxyurea and twice daily radiation, in good induction responders) and of nab-paclitaxel added to hypofractionated radiotherapy for poor responders. II. To ...

Phase

ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment

PRIMARY OBJECTIVES: I. To determine whether 14-21 days of treatment with ACTOplus met XR will result in a decrease in proliferation index (Ki-67) expression in oral cavity/oropharyngeal tumor tissue as compared to placebo. SECONDARY OBJECTIVES: I. Compare differences in proliferation index (Ki-67) expression from baseline to post-exposure in visually normal ...

Phase